Tuesday's Biotech Watch List - Alliqua, BioCryst Pharmaceuticals, Trovagene, Delcath Systems, Array BioPharma PR Newswire CORAL SPRINGS, Florida, July 23, 2013 CORAL SPRINGS, Florida, July 23, 2013 /PRNewswire/ -- FinancialNewsMedia.com issues market news updates for today's active biotech companies: Alliqua, Inc. (OTCQB: ALQA), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Trovagene, Inc. (NASDAQ: TROV), Delcath Systems, Inc. (NASDAQ: DCTH) and Array BioPharma Inc. (NASDAQ: ARRY) Alliqua, Inc. (OTCQB: ALQA) Headline: Alliqua Initiates Proof-of-Principle Study of Transdermal Lidocaine Hydrogel Patch for Pain Relief. Alliqua, Inc. today announced the initiation of a preclinical proof-of-principle study of an experimental hydrogel patch containing lidocaine. Safety and tolerability of Alliqua's lidocaine hydrogel patches will be explored in an animal model. Further, the pharmacokinetic profile will be analyzed to determine the amount of systemic absorption and local lidocaine concentration in the skin immediately beneath the patch. "The ease of use, stability and compatibility with active ingredients make our hydrogels well suited for the transdermal delivery of a variety of compounds, including pain medications like lidocaine," commented James Sapirstein, chief executive officer of Alliqua Biomedical. "Our lidocaine patch development program is just the first in our effort to build a portfolio of products that leverage our hydrogel platform. We believe success in this proof-of-principle study for our lidocaine patch would increase the likelihood of success with other compounds and greatly enhances our efforts in this area. Beyond lidocaine, the Alliqua Biomedical division plans to explore transdermal delivery of dermatological, oncology, antibiotic and neurology products." To read the entire press release, please go to http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=288 FNM Market News: Drug Delivery Technology Market - The $82 billion U.S. drug delivery market is showing no signs of saturation, with major patent expiries, generic competition, tightening Food and Drug Administration (FDA) regulations, and emerging drug delivery systems continuing to provide momentum. Among the 15 drug delivery systems surveyed by Frost & Sullivan, physicians prefer topical delivery, either as a transdermal patch or topical gel/cream, and expressed willingness to switch their current mode of therapy to one available in these forms. BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives. The safety, tolerability, drug exposure and on-target kallikrein inhibition results of this Phase 1 trial strongly support advancing the development program into a Phase 2a study in hereditary angioedema (HAE) patients. Overall, 87 healthy volunteers completed the study; 30 received a single dose of BCX4161 from 50 mg up to 1000 mg, 40 subjects received 100 mg, 200 mg, 400 mg, or 800 mg BCX4161 every eight hours for seven days, and 17 received a placebo. Trovagene, Inc. (NASDAQ: TROV) announces that results emerging from ongoing clinical studies have confirmed the broad applicability of Trovagene technology across a variety of cancer types, and the successful development of a molecular diagnostic test capable of detecting and quantifying oncogene mutations from a simple urine specimen. The ability to regularly detect and monitor the results of cancer treatment through a non-invasive, systemic sample could significantly help patients who require therapy for recurrent or metastatic cancer. Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Tuesday, August 6, 2013 at 4:30 p.m. ET to discuss its financial results for the second quarter of 2013 ended June 30, 2013, and provide an update on recent corporate progress. The dial-in numbers for the conference call are 866-804-6922 (U.S. participants) and 857-350-1668 (international participants); both numbers require passcode 85959025. To access the live webcast, go to the Events & Presentations page on the Investor Relations section of the Company's website at http://www.delcath.com/investors/events/. Array BioPharma Inc. (NASDAQ: ARRY) will report top-line results from a placebo-controlled, randomized, double--blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to discuss those results on Tuesday, July 23, 2013. Ron Squarer, Chief Executive Officer, will lead the call. Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. FinancialNewsMedia.com isaleading provider of third party publishing &news dissemination services.If you would like more information regarding our news coverage solutions, please visithttp://www.financialnewsmedia.comfor more details.Get an edge on the market with ourPremium News Alertsthat are FREE for a limited time athttp://www.financialnewsmedia.com/.Follow us on Facebook:http://www.facebook.com/financialnewsmediaand Twitter:http://twitter.com/FNMgroup.Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PRESS to 545454.(SMS alerts are free, however data rates may apply, check your wireless plan for details.) DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein.FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements. Contact Information: Company: FN Media Group, LLC Contact email: email@example.com U.S. Phone: +1(954)345-0611 URL: http://www.financialnewsmedia.com SOURCE FN Media Group LLC
Erdogan Selects Ahmet Davutoglu as Turkey's Next Prime Minister
Tuesday's Biotech Watch List - Alliqua, BioCryst Pharmaceuticals, Trovagene, Delcath Systems, Array BioPharma
Press spacebar to pause and continue. Press esc to stop.